-
1
-
-
0037353935
-
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life
-
Hellstrom-Lindberg E, Guibrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: Significant effects on quality of life. Br J Haematol 2003;120: 1037-1046.
-
(2003)
Br J Haematol
, vol.120
, pp. 1037-1046
-
-
Hellstrom-Lindberg, E.1
Guibrandsen, N.2
Lindberg, G.3
-
2
-
-
53549108334
-
International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes
-
Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008;83:765-770.
-
(2008)
Am J Hematol
, vol.83
, pp. 765-770
-
-
Kao, J.M.1
McMillan, A.2
Greenberg, P.L.3
-
3
-
-
0036655766
-
Myelodysplastic syndrome overview
-
Kurzrock R. Myelodysplastic syndrome overview. Semin Hematol 2002;39(Suppl. 2):18-25.
-
(2002)
Semin Hematol
, vol.39
, Issue.SUPPL. 2
, pp. 18-25
-
-
Kurzrock, R.1
-
4
-
-
32144431895
-
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making
-
Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 2005;23: 7594-7603.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7594-7603
-
-
Malcovati, L.1
Porta, M.G.2
Pascutto, C.3
-
5
-
-
80053186861
-
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based prognostic scoring system (WPSS)
-
Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011;96:1433-1440.
-
(2011)
Haematologica
, vol.96
, pp. 1433-1440
-
-
Malcovati, L.1
Della Porta, M.G.2
Strupp, C.3
-
6
-
-
30144443817
-
The myelodysplastic syndromes: Diagnosis and treatment
-
Steensma DP, Bennett TM. The myelodysplastic syndromes: Diagnosis and treatment. Mayo din Proc 2006;81:104-130.
-
(2006)
Mayo Din Proc
, vol.81
, pp. 104-130
-
-
Steensma, D.P.1
Bennett, T.M.2
-
7
-
-
0037541576
-
Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes
-
Jansen AJ, Essink-Bot ML, Beckers EA, et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 2003;121:270-274.
-
(2003)
Br J Haematol
, vol.121
, pp. 270-274
-
-
Jansen, A.J.1
Essink-Bot, M.L.2
Beckers, E.A.3
-
8
-
-
70349502130
-
Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review
-
Pinchon DJ, Stanworth SJ, Dorée C, et al. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. Am J Hematol 2009;84:671-677.
-
(2009)
Am J Hematol
, vol.84
, pp. 671-677
-
-
Pinchon, D.J.1
Stanworth, S.J.2
Dorée, C.3
-
9
-
-
0037099753
-
More concern about transfusion requirement when evaluating quality of life in anemic patients
-
Oliva EN, D?Angelo A, Martino B, et al. More concern about transfusion requirement when evaluating quality of life in anemic patients. J Clin Oncol 2002;20:3182-3183.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3182-3183
-
-
Oliva, E.N.1
Dangelo, A.2
Martino, B.3
-
10
-
-
84855965633
-
A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes
-
Oliva EN, Schey C, Hutchings AS. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. Am J Blood Res 2011;1:160-166.
-
(2011)
Am J Blood Res
, vol.1
, pp. 160-166
-
-
Oliva, E.N.1
Schey, C.2
Hutchings, A.S.3
-
11
-
-
84858748853
-
The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes
-
Platzbecker U, Hofbauer LC, Ehninger G, et al. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res 2012;36:525-536.
-
(2012)
Leuk Res
, vol.36
, pp. 525-536
-
-
Platzbecker, U.1
Hofbauer, L.C.2
Ehninger, G.3
-
12
-
-
77953425222
-
Efficace e Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes
-
Caocci G, La Nasa G, Efficace E Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes. Expert Rev Hematol 2009;2:69-80.
-
(2009)
Expert Rev Hematol
, vol.2
, pp. 69-80
-
-
Caocci, G.1
La Nasa, G.2
-
13
-
-
0035366382
-
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to threetimes-weekly dosing
-
Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to threetimes-weekly dosing. J Clin Oncol 2001;19:2875-2882.
-
(2001)
J Clin Oncol
, vol.19
, pp. 2875-2882
-
-
Gabrilove, J.L.1
Cleeland, C.S.2
Livingston, R.B.3
-
14
-
-
33749438404
-
Lenalidomide in the myelodysplastic syndrome with chromosome Sq deletion
-
List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome Sq deletion. N Engl Med 2006;355:1456-1465.
-
(2006)
N Engl Med
, vol.355
, pp. 1456-1465
-
-
List, A.1
Dewald, G.2
Bennett, J.3
-
15
-
-
80053621748
-
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-I-risk myelodysplastic syndromes with delSq
-
Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-I-risk myelodysplastic syndromes with delSq. Blood 2011;118:3765-3776.
-
(2011)
Blood
, vol.118
, pp. 3765-3776
-
-
Fenaux, P.1
Giagounidis, A.2
Selleslag, D.3
-
16
-
-
33745968917
-
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
-
Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108:419-425.
-
(2006)
Blood
, vol.108
, pp. 419-425
-
-
Cheson, B.D.1
Greenberg, P.L.2
Bennett, J.M.3
-
17
-
-
23844489776
-
Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome
-
Oliva EN, Dimitrov BD, Benedetto F, et al. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. LeukRes 2005;29:1217-1219.
-
(2005)
Leuk Res
, vol.29
, pp. 1217-1219
-
-
Oliva, E.N.1
Dimitrov, B.D.2
Benedetto, F.3
-
18
-
-
84856487158
-
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with Sq deletion. A comparative analysis by the groupe Francophone des Myelodysplasies
-
Adès L, Le Bras F, Sebert M, et al. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with Sq deletion. A comparative analysis by the groupe Francophone des Myelodysplasies. Haematologica 2012;97:213-218.
-
(2012)
Haematologica
, vol.97
, pp. 213-218
-
-
Adès, L.1
Le Bras, F.2
Sebert, M.3
-
19
-
-
84885673761
-
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low-or Intermediate-I-risk MDS with del(Sq): A comparative analysis
-
2012 Dec 21[Epub ahead of print]
-
Kuendgen A, Lauseker M, List AF, et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low-or Intermediate-I-risk MDS with del(Sq): A comparative analysis. Leukemia 2012 Dec 21. [Epub ahead of print]
-
Leukemia
-
-
Kuendgen, A.1
Lauseker, M.2
List, A.F.3
-
20
-
-
84885675989
-
Treatment with lenalidomide in myelodysplastic syndromes with deletion Sq: Results from the Dutch named patient program
-
2012 Sep 28[Epub ahead of print]
-
Abouyahya I, Alhan C, Westers TM, et al. Treatment with lenalidomide in myelodysplastic syndromes with deletion Sq: Results from the Dutch named patient program. Leuk Lymphoma 2012 Sep 28. [Epub ahead of print]
-
Leuk Lymphoma
-
-
Abouyahya, I.1
Alhan, C.2
Westers, T.M.3
-
21
-
-
84860744403
-
Continuous lenalidomide treatment for newly diagnosed multiple myeloma
-
Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-1769.
-
(2012)
N Engl J Med
, vol.366
, pp. 1759-1769
-
-
Palumbo, A.1
Hajek, R.2
Delforge, M.3
|